glp-1 and cardiovascular benefits Glucagon-like peptide 1 receptor agonists: mechanisms of action Cardiovascular benefits of obesity therapies:

Although DPP-4 inhibitors do not cross the BBB under normal conditions (the pharmacokinetic feature may prevent their repurposing use in neurodegenerative diseases), the permeability of BBB is increased in neurodegenerative diseases, so molecules otherwise unable to cross BBB could enter into CNS in these conditions (103)

In-Clinic Abortion

In late-stage trials, people taking orforglipron lost an average of about 12% of their body weight over roughly 72 weeks , and head-to-head studies suggest it may outperform standard oral semaglutide tablets (Rybelsus) in both weight loss and blood sugar control

it may ameliorate insulin resistance, inflammation, and protein wasting. Despite the body of evidence to support its use the authors somehow conclude LC administration continues to appeal to nephrologists because its use in dialysis patients has an attractive rationale, it addresses problems that persist despite dialysis, it is safe, and the existing literature does not refute its use

It is possible that the somatotrophs developed increased sensitivity to GHRH as pyridostigmine causes intermediate stimulation of GHRH